RSPHvsFTXHETF Comparison
VS
Invesco S&P 500® Equal Weight Health Care ETF (RSPH) and First Trust Nasdaq Pharmaceuticals ETF (FTXH) belong to the same industry segment: US Health Care. RSPH's top 2 sector exposures are Healthcare and Consumer Non-Cyclicals. In contrast, FTXH's top sector exposures are Healthcare. RSPH is less expensive with a Total Expense Ratio (TER) of 0.4%, versus 0.6% for FTXH. RSPH is up 25.34% year-to-date (YTD) with +$61M in YTD flows. FTXH performs better with 33.54% YTD performance, and +$1.02B in YTD flows. Run a side-by-side ETF comparison of RSPH and FTXH below, and assess how they stack up in performance, liquidity, risk, exposure, holdings, and more, helping you select the best ETF for your investments.
Find out how industry players manage ETF portfolios. Discover our library of Model portfolios
RSPH vs FTXH performance and flow charts
Performance
Cumulative Flows
Historic performance and flows
Data as of 10/30/2026
| 1M | 3M | YTD | 1Y | 3Y | 5Y | ||
|---|---|---|---|---|---|---|---|
| Perf. | RSPH FTXH | +7.26%+4.91% | +13.92%+11.28% | +25.34%+33.54% | +32.12%+50.09% | +60.29%+89.81% | +32.89%+77.86% |
| Flows | RSPH FTXH | +$45M+$48M | +$104M+$135M | +$61M+$1.02B | +$57M+$1.03B | -$224M+$1.02B | -$206M+$1.02B |
Volatility and drawdown
| 3M | 1Y | 3Y | 5Y | ||
|---|---|---|---|---|---|
| Volatility | RSPH FTXH | +18.23%+18.83% | +16.84%+17.65% | +15.92%+17.12% | +16.81%+16.43% |
| Max drawdown | RSPH FTXH | -5.57%-5.45% | -10.87%-7.50% | -16.96%-19.32% | -21.91%-19.32% |
| Max drawdown duration | RSPH FTXH | 55d57d | 116d99d | 434d393d | 817d393d |
Trading data
RSPH | FTXH | |
Last sale 11/2/2026 at 4:55 PM | $39.86 | $43.93 |
| Previous close 10/30/2026 | $39.69 | $44.24 |
| Consolidated volume 10/30/2026 | ||
| Average volume 30 days | ||
| Average discount or premium 30 days | ||
| Average Bid/Ask spread 30 days |
Replication quality
Data as of October 30, 2026
1-year trailing difference
Create an account to view replication metrics
Join for free
RSPH | FTXH | |
|---|---|---|
| Tracking error | ||
| Tracking difference | ||
| 1 year cumulative return difference | ||
| Best | ||
| Worst | ||
| Daily return difference | ||
| Average | ||
| Worst | ||
Advertisement
Main metrics
Last update 11/2/2026 at 4:55 PM
Live
Closed
RSPH | FTXH | |
|---|---|---|
| Last price | $39.86 | $43.93 |
| 1D performance | +0.43% | -0.70% |
| AuM | $982.79 M | $1.18 B |
| E/R | 0.4% | 0.6% |
Characteristics
RSPH | FTXH | |
|---|---|---|
| Management strategy | Passive | Passive |
| Provider | Invesco | First Trust |
| Benchmark | S&P 500 Equal Weight Health Care Index | NASDAQ US Smart Pharmaceuticals Index |
| N° of holdings | 60 | 50 |
| Asset class | Equities | Equities |
| Trailing 12m distribution yield | Join | Join |
| Inception date | November 1, 2006 | September 20, 2016 |
| ESG | No | No |
Advertisement
Exposure
Countries
RSPH
USA
96.84%
Other
3.16%
FTXH
USA
96.23%
Other
3.77%
Sectors
RSPH
Healthcare
98.51%
Other
1.49%
FTXH
Healthcare
99.88%
Other
0.12%
Advertisement
Diversification
RSPH
Total weight of top 15 holdings out of 15
28.14%
FTXH
Total weight of top 15 holdings out of 15
70.94%
Top 15 holdings
Data as of September 30, 2026
RSPH
Moderna, Inc.
2.35%
Illumina, Inc.
2.14%
Revvity, Inc.
1.97%
Agilent Technologies, Inc.
1.96%
Mettler-Toledo International, Inc.
1.94%
Intuitive Surgical, Inc.
1.90%
Thermo Fisher Scientific, Inc.
1.81%
West Pharmaceutical Services, Inc.
1.80%
Danaher Corp.
1.79%
Viatris, Inc.
1.79%
Waters Corp.
1.77%
Biogen, Inc.
1.75%
Veeva Systems, Inc.
1.74%
Amgen, Inc.
1.73%
AbbVie, Inc.
1.71%
FTXH
AbbVie, Inc.
7.37%
Eli Lilly & Co.
7.22%
Pfizer Inc.
7.18%
Merck & Co., Inc.
7.07%
Johnson & Johnson
7.07%
Viatris, Inc.
3.84%
Biogen, Inc.
3.74%
Gilead Sciences, Inc.
3.66%
United Therapeutics Corp.
3.61%
Amgen, Inc.
3.44%
Incyte Corp.
3.42%
Vertex Pharmaceuticals, Inc.
3.38%
Regeneron Pharmaceuticals, Inc.
3.34%
Bristol Myers Squibb Co.
3.34%
Zoetis, Inc.
3.26%
Frequently asked questions about RSPH and FTXH
How have the RSPH and FTXH ETFs performed in 2026?
As of October 30, 2026, RSPH is up 25.34% year-to-date (YTD), while FTXH has returned 33.54%. That puts FTXH better performer ahead so far this year.
Which ETF is attracting more investor money: RSPH or FTXH?
Year-to-date, the RSPH ETF saw +$61M in flows, compared to +$1.02B for FTXH.
Which ETF is more volatile: RSPH or FTXH?
Over the past year, RSPH had a volatility of 16.84%, while FTXH experienced 17.65%.
Which ETF is bigger: RSPH or FTXH?
As of October 30, 2026, RSPH holds $982.79 M in assets under management (AUM), while FTXH manages $1.18 B.
What sectors do the RSPH and FTXH ETFs invest in?
RSPH leans toward sectors like Healthcare. Meanwhile, FTXH focuses on Healthcare.
What are the top holdings of the RSPH ETF and FTXH ETF?
RSPH top holdings include Moderna, Inc., Illumina, Inc. and Revvity, Inc.. FTXH holds in its top three: AbbVie, Inc., Eli Lilly & Co. and Pfizer Inc..
Which ETF is more diversified: RSPH or FTXH?
RSPH holds 60 securities with 28.14% of its assets in the top 15. FTXH has 50 securities and a top 15 weight of 70.94%.
Advertisement
Latest news about RSPH & FTXH
Advertisement
